Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer

Mihai Saftencu 1, Cornelia Braicu 2, Roxana Cojocneanu 2, Mihail Buse 3, Alexandru Irimie 4,5, Doina Piciu 6,7,8, Ioana Berindan-Neagoe 2,3,8

1 Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 40015 Cluj-Napoca, Romania
2 Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 23 Marinescu Street, 40015 Cluj-Napoca, Romania
3 MEDFUTURE-Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, 23 Marinescu Street, 40015 Cluj-Napoca, Romania
4 Department of Surgery, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 40015 Cluj-Napoca, Romania
5 Department of Surgical Oncology and Gynecological Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, 40015 Cluj-Napoca, Romania
6 Department of Nuclear Medicine and Endocrinology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, 40015 Cluj-Napoca, Romania
7 Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, 40015 Cluj-Napoca, Romania
8 Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Republicii 34th street, 400015 Cluj-Napoca, Romania

* Correspondence: doina.piciu@umfcluj.ro

Received: 16 May 2019; Accepted: 13 August 2019; Published: 19 August 2019

Abstract: Background and objectives: Papillary thyroid carcinoma is the most frequent variety of all malignant endocrine tumors. It represents a heterogeneous malignancy with various clinical outcomes, emphasizing the need to identify powerful biomarkers with clinical relevance. Materials and Methods: Available gene expression data (level 3) for thyroid cancers were downloaded from the Cancer Genome Atlas (TCGA), followed by bioinformatic analyses performed on the data set. Results: Based on gene expression analysis, we were able to identify common and specific gene signatures for the three main types of papillary thyroid carcinoma (classical, follicular variant, and tall-cell). The survival rate was not significantly different among the main subtypes, but we were able to identify a biological adhesion signature with impact in patient prognostic. Conclusions: Taken together, the gene expression signature and particular adhesion signature, along with ITGA10 and MSLN in particular, could be used as a prognostic tool with important clinical relevance.

Keywords: thyroid papillary cancer; Cancer Genome Atlas (TCGA); gene expression and biological adhesion signature

1. Introduction

Thyroid cancer is the most common endocrine malignancy, showing an increasing incidence during the last years [1]. Papillary thyroid carcinoma (PTC) has the highest prevalence among all thyroid malignancies, representing around 80% of all thyroid carcinomas [2]. There are three common subtypes of papillary thyroid cancer: classical (conventional), follicular, and tall-cell [2]. The tall-cell phenotype is the most aggressive subtype, showing an increased risk of metastatic dissemination to cervical lymph nodes [2,3].

Genetic and epigenetic alterations are the driving forces of thyroid cancer. There has been an exciting advance in comprehending its molecular pathogenesis during recent years [1,3,4]. In spite of
this fact, there are still various issues related to the pathogenic mechanisms behind thyroid cancer that need to be solved, such as the identification of various genes, mutations, epigenetic alterations, and environmental factors implicated in its progress [5–7]. To manage the limitations related to molecular pathogenesis, many researchers have attempted to identify useful genetic tools [1,4,8]. Such tools for transcriptomic analysis are expected to provide novel information with clinical relevance, in order to improve the management and the outcome of this disease [9–11].

The Cancer Genome Atlas (TCGA) is a large database of molecular data for a wide range of cancer types, including genome and transcriptome evaluation, selected in a laborious and consistent manner [7,12,13]. These furnish remarkable possibilities for complex data analyses and for detecting trends of alteration of transcriptomic patterns. This kind of analysis will lead to novel insight into the management of thyroid malignancies.

The current study was focused on the evaluation of global gene expression pattern in papillary thyroid carcinoma tissue and its related main types (classical, follicular, and tall-cell) compared with adjacent normal tissue, in order to identify differentially expressed genes. Then, we integrated the altered gene expression signature in biological context, trying to identify the main pathways and biological processes impacting the development of new biomarkers of thyroid cancer.

2. Materials and Methods

2.1. Gene Expression Evaluation Based on TCGA Data

Papillary thyroid cancer RNA sequencing data (systematized on its main subtypes) as well as matched adjacent noncancerous control data was used to evaluate the global alteration in gene expression pattern. This data was downloaded from the TCGA module database of the UCSC (University of California Santa Cruz) Xena browser, in the form of data matrices containing log2, normalized expression data, together with clinical and demographic information of the patients. We included 357 patients with classical PTC, 102 with the follicular variant of PTC, and 36 with tall-cell PTC (Table 2). We used the GeneSpring Gx analysis software (provided by Agilent Technologies, Santa Clara, CA, USA) in order to evaluate both the global and the characteristic subtypical alterations in PTC. As a cut-off value, we used a fold change of $\pm 2$ and a $p$-value $< 0.05$, corrected using the Benjamini–Hochberg method to restrain the false discovery rate (FDR) resulted in multiple testing.

| Table 1. Demographic, pathologic and clinical characteristics of TCGA samples for PTC. |
|--------------------------------------------|-------------------|-------------------|-------------------|
| Demographics Papillary Thyroid Carcinoma ($n = 505$) | Classical ($n = 358$) | Follicular ($n = 102$) | Tall Cell ($n = 36$) |
| Sex | | | |
| Males | 98 | 27.3% | 24 | 23.53 % | 9 | 25.00% | 5 | 55.56% |
| Females | 260 | 72.7% | 78 | 76.47% | 27 | 75.00% | 4 | 44.44% |
| Age | | | | |
| Median, Range | 45.5–15–88 | 46, 16–83 | 46, 28–89 | 46, 22–62 |
| Median, Range♂ | 51, 15–88 | 51, 16–80 | 51.5, 38–85 | 37, 22–60 |
| Focus type | | | | |
| Unilocal | 203 | 56.7% | 51 | 50.00% | 11 | 30.56% | 3 | 33.33% |
| Multilocal | 148 | 41.34% | 50 | 49.02% | 23 | 63.89% | 6 | 66.67% |
| Unknown | 7 | 1.96% | 1 | 0.98% | 2 | 5.56% | - | - |
| T1 | 103 | 28.77% | 32 | 31.37% | 7 | 19.44% | 1 | 11.11% |
| T2 | 122 | 34.08% | 40 | 39.22% | 3 | 8.33% | 1 | 11.11% |
| T3 | 111 | 31.01% | 28 | 27.45% | 25 | 69.44% | 7 | 77.78% |
| T4 | 20 | 5.59% | 2 | 1.96% | 1 | 2.78% | - | - |
| T unknown | - | - | - | - |
| N0 | 149 | 41.62% | 65 | 63.73% | 13 | 36.11% | 3 | 33.33% |
| N1 | 184 | 51.40% | 50 | 49.02% | 23 | 63.89% | 6 | 66.67% |
| N2 | - | - | - | - |
| N unknown | - | - | - | - |
| M0 | 222 | 62.01% | 65 | 63.73% | 13 | 36.11% | 4 | 44.44% |
| M1 | 4 | 1.12% | 5 | 4.90% | - | - |
| M unknown | 1 | 0.28% | - | - |
Table 2. Cont.

| Demographics | Papillary Thyroid Carcinoma (n = 505) | Follicular (n = 102) | Other (n = 9) |
|--------------|-------------------------------------|---------------------|--------------|
| Tumor stage  | I 212 59.22 56 54.90 10 27.78 6 66.67 | II 29 8.10 22 21.57 - 1 11.11 | III 73 20.39 18 17.65 20 55.56 1 11.11 |
|              | IV 43 12.01 5 4.90 6 16.67 1 11.11 | Unknown 1 0.28 1 0.98 - - | Right lobe 141 39.39 59 57.84 12 33.33 3 33.33 |
|              |                                   | Left lobe 132 36.87 30 29.41 12 33.33 2 22.22 | Bilateral 63 17.60 10 9.80 9 25.00 4 44.44 |
|              |                                   | Anatomic site | Ischemus 17 4.75 2 1.96 3 8.33 - | Goiter 4 1.12 - - |
|              |                                   | Cancer 1 0.28 - - | Hashimoto 1 0.28 - - |
| Teatment site | Right lobe 141 39.39 59 57.84 12 33.33 3 33.33 | Bilateral 63 17.60 10 9.80 9 25.00 4 44.44 | Bilateral 63 17.60 10 9.80 9 25.00 4 44.44 |
|              | Normal 209 58.38 43 42.16 22 61.11 6 66.67 | Normal 209 58.38 43 42.16 22 61.11 6 66.67 | Normal 209 58.38 43 42.16 22 61.11 6 66.67 |
| Response to   | Complete response 107 29.89 31 30.39 20 55.56 5 55.56 | Complete response 107 29.89 31 30.39 20 55.56 5 55.56 | Complete response 107 29.89 31 30.39 20 55.56 5 55.56 |
| therapy       | Partial response 107 29.89 31 30.39 20 55.56 5 55.56 | Partial response 107 29.89 31 30.39 20 55.56 5 55.56 | Partial response 107 29.89 31 30.39 20 55.56 5 55.56 |
|              | Radiological progressive disease 5 1.40 - - | Radiological progressive disease 5 1.40 - - | Radiological progressive disease 5 1.40 - - |
|              | Stable disease 2 0.56 - - | Stable disease 2 0.56 - - | Stable disease 2 0.56 - - |
|              | Unknown 229 63.97 68 66.67 13 36.11 4 44.44 | Unknown 229 63.97 68 66.67 13 36.11 4 44.44 | Unknown 229 63.97 68 66.67 13 36.11 4 44.44 |

TNM-tumour stage, lymph nodes, metastases.

2.2. Pathway Enrichment and Biological Process Analysis, Gene Ontology Classification, and Network Visualization

Pathway enrichment analysis, biological process analysis and gene ontology classification were performed for genes with an altered expression level by using the online Panther tool (http://www.pantherdb.org) [14]. STRING (https://string-db.org) and miRNET (https://www.mirnet.ca/miRNet/faces/home.xhtml) were used to determine gene involvement in PTC pathogenesis and for the inclusion of altered genes in key regulatory network.

3. Results

3.1. Differential Gene Expression in Tumor Tissues versus Normal Tissues for PTC

Global gene expression was evaluated in tumor tissues (n = 505) versus normal tissues (n = 59), considering as cut-off value the FC (fold change) of ±2 and corrected p-value ≤ 0.05. A total of 1120 upregulated genes and 1191 downregulated genes were identified.

Figure 1A shows the hierarchical clustering of the genes on thyroid cancer, providing evidence that PTC can be classified on its own distinct expression pattern, emphasizing the diversity and heterogeneity of PTC. Significantly enriched biological processes of differentially expressed genes are presented in Figure 1B,C.
Figure 1. Hierarchical clustering and gene ontology classification for gene expression data in papillary thyroid cancer versus normal thyroid tissue. (A) Heatmap for papillary thyroid cancer, using malignant tissues ($n = 505$) and normal tissues ($n = 59$). Significantly overexpressed genes are highlighted in red and underexpressed genes are shown in blue, emphasizing distinct PTC subtypes with clinical and biological relevance; (B) and (C) Biological classification, based on the gene expression signature, in tumor versus normal tissue in PTC patients (by using the online PantherDB tool). (TN: normal thyroid tissue, TT-tumor thyroid tissue).

The functional pattern of miRNA–mRNA regulatory network has been shown to be involved in both tumor initiation and progression in several cancers, including PTC. Using a miRNET tool allowed us to emphasize the crucial role of the interconnection between the miRNA and mRNA networks, as well as taking into consideration the gene ontology classification (KEGG or Reactome). Based on KEGG (Kyoto Encyclopedia of Genes and Genomes) classification, most of the downregulated genes belong to the Hedgehog signaling pathway ($p$-value 0.000212), Axon guidance ($p$-value 0.0359), basal cell carcinoma ($p$-value 0.0373), displayed in Figure 2A. Reactome classification revealed the downregulation of genes related to thyroxine biosynthesis ($p$-value 0.00339), neuronal system ($p$-value 0.102) or developmental biology ($p$-value 0.102), presented in Figure S1A. Regarding up-regulated genes, KEGG classification reveals that up-regulated genes are involved in altered pathways belonging to the p53 signaling pathway ($p$-value 0.000254), ECM (extracellular matrix)-receptor interaction ($p$-value 0.000254) and pathways in cancer ($p$-value 0.0935), displayed in Figure 2B. Reactome classification of up-regulated genes reveals their involvement in extracellular matrix organization ($p$-value $1.74 \times 10^{-12}$), degradation of the extracellular matrix ($p$-value $2.6 \times 10^{-10}$) and collagen degradation (0.0000149), presented in Figure S1B.
Figure 2. The representative miRNA-gene network interactions between the genes with an altered expression levels when comparing tumor to normal tissue and their respective miRNAs, generated using miRNet. (A) shows mRNA–miRNA network for down-regulated genes in PTC, involved in the Hedgehog signaling pathway (n = 15, p-value = 0.000212), Axon guidance (n = 18, p-value = 0.0359) and basal cell carcinoma (n = 10, p-value = 0.0373), while (B) shows mRNA–miRNA network for up-regulated genes in PTC, associated with the p53 signaling pathway (n = 16, p-value = 0.0000254), ECM-receptor interaction (n = 18, p-value = 0.0000254) and pathways in cancer (n = 29, p-value = 0.0935). The genes belonging to these aforementioned pathways are highlighted with blue dots, while the red dots represent the genes with altered expressions involved in other interconnected pathways. The blue squares represent the miRNAs that target the altered genes, where the size of the square is proportional to the number of signaling pathways involved (based on KEGG classification).

3.2. Analysis of Gene Expression Pattern in the Main Types of Thyroid Cancer

The survival rates of patients with PTC were not significantly different (Figure 3A), despite the fact that important alterations among the three selected subtypes of PTC were observed (classical PTC versus adjacent normal tissue, follicular PTC versus adjacent normal tissue, and tall-cell PTC versus adjacent normal tissue). The frequencies of genes showing altered expression, according to the three main types of PTC, sorted by the upregulation and downregulation criteria, are graphically represented as a Venn diagram in Figure 3B. Among the three PTC we identified, 196 upregulated and 353 downregulated genes as common gene expression signature. Figure 3E,F emphasize the gene network for the common signature specific for the downregulated and overexpressed genes. These data will lead to the identification of new common players in PTC, emphasizing the important role of TP53 signaling and cell cycle regulators.

A GO enrichment analysis was performed (using the Panther online tool) in order to gain a better understanding of gene functions and signaling pathways in altered genes for the three main PTC subgroups. The top 10 enriched pathways of upregulated and downregulated genes (generated by the Panther gene ontology online tool) for the main three types of PTC are shown in Figure 4, this determining the basis of the main altered mechanisms that represent an important direction for future experimental research.
Figure 3. Molecular portrait of thyroid cancer. (A) Kaplan–Meier survival analysis, categorized by the main 3 types of papillary thyroid cancer; (B) Heatmap for specific altered genes for the three selected groups versus TN (normal thyroid tissue), considering p-value $1 \times 10^{-30}$; (C,D) Venn diagram for identifying common and specific upregulated or downregulated genes in each subtype of PTC; (E) String network for the common 196 overexpressed genes; (F) String network for the common 353 downregulated genes.
3.3. Analysis of Biological Adhesion Signature in Papillary Thyroid Cancer

Cellular adhesion mechanisms have an important role in PTC. These mechanisms are specifically activated in all the three subtypes of PTC, albeit more pronounced in the classical and tall-cell subgroups, while the follicular variant of PTC shows a less pronounced activation.

We performed pre-ranked gene set enrichment analysis (using the Panther online tool) for the three main subtypes of PTC in order to be able to functionally interpret the biological adhesion signatures. This gene list, annotated as ‘biological adhesion’, was integrated in STRING in order to determine the gene interactions among each specific group.

This analysis is graphically represented by: a Circos plot for the overexpressed genes (Figure 4A) and downregulated genes (Figure 4B); a Venn diagram for the altered genes involved in biological
adhesion (Figure 5A,B); and by an interconnected network (generated using the STRING tool) for the overexpressed and downregulated genes involved in biological adhesion (Figure 5C,D).

Figure 5. The involvement of biological adhesion molecules in papillary thyroid cancer. Venn diagram for identifying the specific and common (A) upregulated genes and (B) downregulated genes related to biological adhesion in classic, follicular variant, and tall-cell PTC. Biological adhesion molecules interaction network (generated using STRING): (C) upregulated genes and (D) downregulated genes.

3.4. Association of Key Genes Expression Related to Biological with Survival of Patients with Papillary Thyroid Carcinoma

Survival analysis based on TCGA data showed that the expression levels of CDH13, CDH24, CDH6, ICAM1, ITGA10, ITGA6, ITGA7, ITGAX, ITGB6, MCAM, MSLN, NOTCH4, and TGFBI genes were not associated with the overall survival rate of patients with follicular type and tall-cell PTC (Figure 6).

For the case of the ITGA10 gene, the FC was: 1.33 for the classical subtype (below the threshold limit cut-off of the FC ± 2, p-value = 0.021); 2.38 for follicular subtype (p-value = 0.025); and 1.174 for the tall-cell subtype (p-value = 0.874). Similarly, for the MSLN gene, the FC was: 4.54 for the classical...
subtype ($p$-value = $2.4 \times 10^{-8}$); 1.01 for follicular subtype ($p$-value = 0.93); and 2.34 for the tall-cell subtype ($p$-value = 0.511). These results can be seen in Figure 6A,B, respectively.

**Figure 6.** Bar graphs of the global expression levels of (A) ITGA10 (Integrin Subunit Alpha 10) and (B) MSLN (Mesothelin) expressions in the investigated PTC subtypes, generated using the TCGA data analysis (* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$). The heatmap representations of the individual expression levels of ITGA10 and MSLN in the investigated subtypes of papillary thyroid cancer: (C) classical, (D) follicular and (E) tall-cell versus TN (normal tissue).

The heatmap representations, seen in Figure 6C–E, emphasize the expression level in normal and tumor tissues for ITGA10 and MSLN. As can been seen in Figure 7, either the high gene expression of ITGA10 or low gene expression of MSLN was correlated to a significant decrease in the disease-free overall survival of patients with classical PTC. The rest of the evaluated genes presented no statistically significant correlation between overall survival rate and gene expression levels.

**Figure 7.** Kaplan–Meier survival analysis for high and low expression levels of ITGA10 and MSLN in classic PTC, based on TCGA data analysis.
4. Discussions

In the present study, we evaluated and analyzed the difference of the expression profiles of mRNAs in PTC, emphasizing the common and specific miRNA signatures for its three main subtypes: classical, follicular, and tall-cell. These findings were also verified through functional and pathway enrichment analyses. Comparing the gene–gene and gene–miRNA interactions of the genes exhibiting an altered expression level is a useful method for both discerning dysregulated pathways in the process of the disease [15] and pointing out the crosstalk between signaling pathways, as can be seen in Figure 2. Expanding evidence shows that p53 family members lead to the advancement of thyroid cancer [16], and our research also identified activated genes related to this signaling pathway.

The malignant development and progression are influenced by the fact that thyroid hormone synthesis system is downregulated in PTCs due to de-differentiation [17], revealing the relation to thyroxine biosynthesis (Reactome classification). Recent studies have further shown promising outcomes following chemical reduction of thyroid hormones or inhibition, or their binding to the integrin receptor, to have positive impact in patient prognostic [17].

A previous study accentuated the importance of metabolic gene signatures in PTC [18]. Another similar study identified 719 genes with altered expression levels and, through KEGG pathway enrichment analyses of the overexpressed genes, demonstrated the association to focal adhesions, ECM-receptor interactions, adherents junctions, and 12 other pathways; all these overexpressed genes belong to biological adhesions mechanisms [19], and all these belong to biological adhesions mechanisms. These are directly related to key cellular processes including motility, proliferation, differentiation, regulation of gene expression, and cell survival [19,20], which are explicitly altered in many cancer types. Also, it has been previously stated that thyroid cancers can activate the immunologic pathway and biological adhesion pathways, a fact consistent with our observation in all three subtypes of PTC [21]. Cell adhesion molecules mediate important cellular interactions involved in tumor progression [22]. It was observed that the alteration in the gene expression pattern of cell adhesion molecules has been involved in all steps of tumor progression, including tumor cell detachment from primary site, cellular intravasation and extravasation [22,23].

In the case of downregulated genes, we observed a connection to the Hedgehog pathway, this emphasizing the dual role of these signaling pathways. As previously presented, it has the capacity to crosstalk with RAS/BRAF/MEK pathway and ligand secretion by tumor stroma, inducing cancer cell migration and in vitro tumorigenesis [24].

The classical PTC is a particular subtype where the alteration of adhesion molecules seems to have an important role in tumor progression. A previous profiling study revealed similar altered mechanisms, where overexpressed genes were related mainly to cell adhesion processes, protease binding, or ECM-receptor interactions [25]. ICAM-1 (Intercellular adhesion molecule 1) is an important molecule that has an important role in cell adhesion regulation and in the inflammatory response progression [26]. It was previously proven that ICAM-1 is upregulated in both classical and tall-cell PTC, therefore it could be considered a biomarker of PTC progression [26].

Although the previously established biomarkers for predicting clinical outcomes based on molecular markers related to adhesion molecules have not been a proof of success in clinical management of PTC, it is still relevant to determine the accurate and generalized predictive signatures in this type of cancer. Our study accentuated for the first time a correlation of the overall survival rate to ITGA10 and MSLN in classic PTC. ITGA10 was proved to have an important role in adhesion, migration and/or in the regulation of inflammatory responses [27]. MSLN was observed in several cancer types, meaning it represents an important therapeutic immunological target [28]. Inhibition of MSLN reversed mesenchymal features and attenuated stem cell properties, in addition to inhibiting tumor growth and metastasis in lung cancer models; this could be exploited also for thyroid cancer [29]. Therefore, additional biological adhesion and immunological genes could be utilized to estimate the prognostic impact of the different subtypes of thyroid cancer.
5. Conclusions

In conclusion, our work demonstrated that the transcriptomic evaluation and pathway analysis have an important role in understanding the mechanism related to tumorigenesis and tumor progression in papillary thyroid cancer. The specific and common gene expression signature provided better insights into the molecular characteristics of these malignancies.

This work demonstrated a methodology of database analysis for determining gene expression patterns useful for the identification of PTC patients specific subtypes based on biological adhesion signature (particularly TGA10 and MSLN). Further characterizing this signature could facilitate the discovery of novel prognostic and predictive factors that could guide a personalized treatment approach to PTC. Forthcoming investigations should attempt to clinically and experimentally validate mRNA expression-based adhesion molecules’ expression level by PTC subtypes. We are looking forward to additionally clarifying their biological relevance through further validation.

Supplementary Materials: The following are available online at http://www.mdpi.com/1010-660X/55/8/500/s1, Figure S1. Interconnected gene network with specific miRNAs, generated using miRnet. (A) mRNA–miRNA network for down-regulated genes in PTC (based on Reactome classification) was related to thyroxine biosynthesis, neuronal system or developmental biology; (B) up-regulated genes in PTC (based on Reactome classification) were related to extracellular matrix organization, degradation of the extracellular matrix, and collagen degradation. Figure S2. Bar graphs, displaying the enriched GO of differential expressed genes (using the Panther Gene Ontology online tool) for the main subtypes of papillary thyroid cancer: (A) classic, (B) follicular variant and (C) tall-cell.

Author Contributions: M.S. and C.B. was manuscript writing and data integration, C.B. was responsible for literature study used for introduction and discussion section. R.C. and M.B. was responsible for bioinformatics data analysis, A.I. and D.P. was responsible for proof reading of the manuscript, I.B.-N. was responsible for the conceptualization of the study and the final proof editing. All the authors contributed to the manuscript writing and approved the final version of the manuscript.

Funding: This study was supported by research grant no. 4995/5/08.03.2016 from “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania. Also was partially supported by a PN-III-P1-1.2-PCDI2017-0737: Genomic population mapping of radioactively and heavy metals contaminated areas in order to increase national security-ARTEMIS and by Funding Agency-Ministry of Research and Innovation PNCDI III 2015–2020 “Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers”—ECHITAS, no. 29PFE/18.10.2018.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Xing, M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 2013, 13, 184–199.
2. Shi, X.; Liu, R.; Basolo, F.; Giannini, R.; Shen, X.; Teng, D.; Guan, H.; Shan, Z.; Teng, W.; Musholt, T.J.; et al. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. J. Clin. Endocrinol. Metab. 2016, 101, 264–274. [CrossRef] [PubMed]
3. Parameswaran, R.; Brooks, S.; Sadler, G.P. Molecular pathogenesis of follicular cell derived thyroid cancers. Int. J. Surg. 2010, 8, 186–193. [CrossRef] [PubMed]
4. Riesco-Eizaguirre, G.; Santisteban, P. ENDOCRINE TUMOURS: Advances in the molecular pathogenesis of thyroid cancer: Lessons from the cancer genome. Eur. J. Endocrinol. 2016, 175, R203–R217. [CrossRef]
5. Tomuleasa, C.; Braicu, C.; Irimie, A.; Craciun, L.; Berindan-Neagoe, I. Nanopharmacology in translational hematology and oncology. Int. J. Nanomed. 2014, 9, 3465–3479.
6. Braicu, C.; Catana, C.; Calin, G.A.; Berindan-Neagoe, I. NCRNA combined therapy as future treatment option for cancer. Curr. Pharm. Des. 2014, 20, 6565–6574. [CrossRef] [PubMed]
7. Irimie, A.I.; Braicu, C.; Cojoneanu, R.; Magdo, L.; Onaciu, A.; Ciocan, C.; Mehterov, N.; Dudea, D.; Buduru, S.; Berindan-Neagoe, I. Differential Effect of Smoking on Gene Expression in Head and Neck Cancer Patients. Int. J. Environ. Res. Public Health 2018, 15, 1558. [CrossRef] [PubMed]
8. Kim, H.S.; Kim, D.H.; Kim, J.Y.; Jeoung, N.H.; Lee, I.K.; Bong, J.G.; Jung, E.D. Microarray analysis of papillary thyroid cancers in Korean. Korean J. Intern. Med. 2010, 25, 399–407. [CrossRef] [PubMed]
9. Chen, S.; Fan, X.; Gu, H.; Zhang, L.; Zhao, W. Competing endogenous RNA regulatory network in papillary thyroid carcinoma. *Mol. Med. Rep.* 2018, 18, 695–704. [CrossRef] [PubMed]

10. Balacescu, O.; Balacescu, L.; Tudoran, O.; Tudor, N.; Rus, M.; Buiga, R.; Susman, S.; Fetica, B.; Pop, L.; Maja, L.; et al. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. *BMC Cancer* 2014, 14, 246. [CrossRef] [PubMed]

11. Berindan-Neagoe, I.; Balacescu, O.; Burz, C.; Braicu, C.; Balacescu, L.; Tudoran, O.; Cristea, V.; Irimie, A. p53 gene therapy using RNA interference. *J. BUON Off. J. Balk. Union Oncol.* 2009, 14 (Suppl. 1), S51–S59.

12. Chu, A.; Robertson, G.; Brooks, D.; Mungall, A.J.; Birol, I.; Coope, R.; Ma, Y.; Jones, S.; Marra, M.A. Large-scale profiling of microRNAs for The Cancer Genome Atlas. *Nucleic Acids Res.* 2016, 44, e3. [CrossRef] [PubMed]

13. Mi, H.; Muruganujan, A.; Huang, X.; Ebert, D.; Mills, C.; Guo, X.; Thomas, P.D. Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). *Nat. Protoc.* 2019, 14, 703–721. [CrossRef]

14. Ao, Z.X.; Chen, Y.C.; Lu, J.M.; Shen, J.; Peng, L.P.; Lin, X.; Peng, C.; Zeng, C.P.; Wang, X.F.; Zhou, R.; et al. Identification of potential functional genes in papillary thyroid cancer by co-expression network analysis. *OncoLett.* 2018, 16, 4871–4878. [CrossRef]

15. Manzella, L.; Stella, S.; Pennisi, M.S.; Tirrone, E.; Massimino, M.; Romano, C.; Puma, A.; Tavarelli, M.; Vigneri, P. New Insights in Thyroid Cancer and p53 Family Proteins. *Int. J. Mol. Sci.* 2017, 18, 1325. [CrossRef]

16. Kraśnin, E.; Piekielko-Witkowska, A.; Ellis, M.; Ashur-Fabian, O. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. *Front. Endocrinol.* 2019, 10, 59.

17. Ma, B.; Jiang, H.; Wen, D.; Hu, J.; Han, L.; Liu, W.; Xu, W.; Shi, X.; Wei, W.; Liao, T.; et al. Transcriptome analyses identify a metabolic gene signature indicative of dedifferentiation of papillary thyroid cancer. *J. Clin. Endocrinol. Metab.* 2019, 104, 3713–3725. [CrossRef] [PubMed]

18. Han, J.; Chen, M.; Wang, Y.; Gong, B.; Zhuang, T.; Liang, L.; Qiao, H. Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma. *Sci. Rep.* 2018, 8, 9912. [CrossRef] [PubMed]

19. Wendl, M.C.; Wallis, J.W.; Lin, L.; Kandoth, C.; Mardis, E.R.; Wilson, R.K.; Ding, L. PathScan: A tool for discerning mutational significance in groups of putative cancer genes. *Bioinformatics* 2011, 27, 1595–1602. [CrossRef]

20. Kim, K.; Jeon, S.; Kim, T.-M.; Jung, C.K. Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes. *Cancers* 2018, 10, 494. [CrossRef] [PubMed]

21. Kobawala, T.P.; Trivedi, T.I.; Gajjar, K.K.; Patel, D.H.; Patel, G.H.; Ghosh, N.R. Significance of NF-κB and the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma. *J. Thyroid Res.* 2016, 2016, 8143695. [CrossRef]

22. Makrilia, N.; Kollias, A.; Manolopoulos, L.; Syrigos, K. Cell adhesion molecules: Role and clinical significance in cancer. *Cancer Invest.* 2009, 27, 1023–1037. [CrossRef] [PubMed]

23. Parascandolo, A.; Leukkanen, M.O.; De Rosa, N.; Ugolini, C.; Cantisani, M.C.; Cirafici, A.M.; Basolo, F.; Santoro, M.; Castellone, M.D. A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: Crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma. *Oncotarget* 2018, 9, 4496–4510. [CrossRef]

24. Zhang, K.E.; Ge, S.-J.; Lin, X.-Y.; Lv, B.-B.; Cao, Z.-X.; Li, J.-M.; Xu, J.-W.; Wang, Q.-X. Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto’s thyroiditis. *Oncol. Lett.* 2016, 11, 1722–1730. [CrossRef] [PubMed]
27. Lemma, S.A.; Kuusisto, M.; Haapasaari, K.M.; Sormunen, R.; Lehtinen, T.; Klaavuniemi, T.; Eray, M.; Jantunen, E.; Soini, Y.; Vasala, K.; et al. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. *Carcinogenesis* **2017**, *38*, 812–820. [CrossRef]

28. Hassan, R.; Thomas, A.; Alewine, C.; Le, D.T.; Jaffee, E.M.; Pastan, I. Mesothelin Immunotherapy for Cancer: Ready for Prime Time? *J. Clin. Oncol.* **2016**, *34*, 4171–4179. [CrossRef] [PubMed]

29. He, X.; Wang, L.; Riedel, H.; Wang, K.; Yang, Y.; Dinu, C.Z.; Rojanasakul, Y. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. *Mol. Cancer* **2017**, *16*, 63. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).